Navigation Links
TPI to Host Fiscal Year 2011 Earnings Conference Call on Tuesday, September 27, 2011 at 9:00 a.m. ET
Date:9/21/2011

CHENGDU, China, Sept. 21, 2011 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and active pharmaceutical ingredients (API), today announced that the earnings conference call for the fiscal year 2011 ending June 30, 2011 will be held at 9:00 a.m. Eastern Time on Tuesday, September 27, 2011.

Interested parties may access the call by dialing 1-877-941-2068 (U.S.) or 1-480-629-9712 (International).

The conference ID is 4474328. It is advisable to dial in approximately 5 minutes prior to the start of the call.

A replay will be available by calling 1-877-870-5176 or 1-858-384-5517 (International) from 09/27/2011 at 12:00 noon Eastern Time to 10/11/2011 at 11:59 pm Eastern Time.

Replay Pin Number:  4474328

This call is being web cast by ViaVid Broadcasting and can be accessed at the following link: http://viavid.net/dce.aspx?sid=00008D3F

About TPIHeadquartered at Chengdu, China, TPI is a pharmaceutical company that specializes in the development, manufacturing, marketing and sales of patented biopharmaceutical, modernized traditional Chinese medicines, branded generics and other pharmaceuticals. TPI currently manufactures a comprehensive portfolio of 58 products, 24 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI's pipeline targets various high incidence healthcare indications. TPI has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.

For more information about TPI, please visit:  http://www.tianyinpharma.com.

Safe Harbor StatementThe Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:Investors Contact: ir@tianyinpharma.com Web:   http://www.tianyinpharma.com Tel: +86-28-8551-6696 (Chengdu, China)+86 134-36-550011 (China)Address:23rd Floor Unionsun Yangkuo PlazaNo. 2, Block 3, South Renmin RoadChengdu, 610041China
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2011 Fourth Quarter Results; Teleconference and Webcast to be held on September 22, 2011
2. China Botanic Pharmaceutical Reports Third-Quarter Fiscal Year 2011 Results
3. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
4. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2012
5. China Cord Blood Corporation to Report First Quarter Fiscal 2012 Financial Results
6. Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
7. K-V Pharmaceutical Company Announces Filing of Fiscal 2011 Form 10-K and Schedules Investor Conference Call
8. China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2011
9. China Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2011 Financial Results
10. Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 Results
11. SeraCare Reports Second Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... Diversity focused business accelerator, The ... Growth pitch competition to uncover the top technology-driven, women-led startups in Boston, MA, New ... of each city’s entrepreneurial events going on that week – in Boston, it will ...
(Date:9/20/2017)... Palo Alto, CA (PRWEB) , ... September 20, ... ... and public interest organization focused on molecular manufacturing and other transformative technologies, announced ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/19/2017)... ... , ... VetStem Biopharma ’s CEO and founder, Dr. Bob Harman DVM, MPVM, is featured ... Cell Therapy: A Rising Tide". Dr. Harman and Dr. Riordan met in 2003 and ... in the potential of stem cell therapy and a fast friendship was formed. , Dr. ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... today announced a partnership with Cytena GmbH to launch the CloneSelect™ Single-Cell Printer™ ... image analysis to isolate single cells and provide visual documentation of monoclonality for ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 No two people are ... the New York University Tandon School of Engineering ... found that partial similarities between prints are common ... mobile phones and other electronic devices can be ... vulnerability lies in the fact that fingerprint-based authentication ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
Breaking Biology News(10 mins):